Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (August 2026)
52 slides from Cantargia Ab's investor presentation, August 2026
Slide 1: Blocking the RIGHT signals to improve treatment options
Blocking the RIGHT signals to improve treatment options Corporate Presentation August 2026 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia Is the Preeminent IL1RAP-Focused Company
Cantargia Is the Preeminent IL1RAP-Focused Company → IL1 Receptor Accessory Protein (IL1RAP) is a co-receptor required for downstream signaling of IL-1, IL-33 and IL-36 → Targeting IL1RAP impacts three signaling systems to counteract redundancy and increase efficacy → IL1RAP biology links innate and
Slide 4: Our IL1RAP-Focused Pipeline
Our IL1RAP-Focused Pipeline Asset Target Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Partner Oncology PDAC + Daraxonrasib - Phase 1b Planned Nadunolimab IL1RAP MDS/AML1 Investigator-Initiated Trial CANxx Unique IL1RAP platform2 Autoimmune CAN14 IL1RAP BsAb3 Autoimmune diseases CAN10 IL1
Slide 5: Executive Management Team with Extensive Experience
Executive Management Team with Extensive Experience Hilde Steineger Patrik Renblad David Liberg Ton Berkien CEO CFO CSO CBO EXECUTIVE TEAM WITH COMPREHENSIVE INDUSTRY INSIGHT 5
Slide 6: Cantargia – Oncology
CANTARGIA – ONCOLOGY
Slide 7: Why We're Pursuing IL1RAP with Nadunolimab in Oncology
Why We're Pursuing IL1RAP with Nadunolimab in Oncology → High expression of IL1RAP strongly correlates to poorer prognosis in multiple tumor types → Intricately involved in tumorigenesis across multiple downstream pathways; Transcription factor NFκB and AP-1 are associated with cellular survival, pr
Slide 8: Pancreatic Ductal Adenocarcinoma – PDAC
PANCREATIC DUCTAL ADENOCARCINOMA – PDAC
Slide 9: High IL1RAP Expression Is Linked to Poor Outcome in KRAS mutated Pancreatic Tumors
High IL1RAP Expression Is Linked to Poor Outcome in Patients with KRAS mutated Pancreatic Tumors OS from diagnosis - KYT OS from diagnosis – KYT w KRAS mutation → High IL1RAP RNA expression in PDAC tumors correlate with poor survival → IL1RAP levels strongly influence survival in allcomers as well a
Slide 10: IL1RAP Is Expressed by Tumor Cells, Myeloid Cells and Fibroblasts in the PDAC TME
IL1RAP Is Expressed by Tumor Cells, Myeloid Cells and Fibroblasts in the PDAC TME → Single-cell RNA sequencing of tumors from PDAC patients (n=16) shows IL1RAP is mainly expressed by granulocytes, macrophages, tumor cells and fibroblasts in the tumor microenvironment (TME) → Growing body of evidence
Slide 11: IL1RAP Is a Fundamental Driver in the PDAC TME
IL1RAP Is a Fundamental Driver in the PDAC TME → IL1RAP is expressed as a signaling receptor on tumor cells, myeloid cells and cancer-associated fibroblasts (CAFs) → IL-1 cytokines are induced in tumor cells Onco-immune network and activate myeloid cells and CAFs in the mediates: TME, feedforward si
Slide 12: IL1RAP Targeting in a Treatment Resistant Preclinical Model of PDAC
IL1RAP Targeting has Distinct Effects in an Aggressive and Treatment Resistant Preclinical Model of PDAC m-Nadunolimab reprograms the TME in PKT mice potently inhibits tumor growth and alleviates immune suppression In collaboration with Jashodeep Datta, MD PhD, Sylvester Comprehensive Cancer Center,
Slide 13: PDAC: A Deadly Cancer with Limited Treatment Options
PDAC: A Deadly Cancer with Limited Treatment Options LOCALLY ADVANCED OR METASTATIC DISEASE Median survival: → 8.5 – 11.7 mo Treatments: → Gemcitabine + nab-paclitaxel → Gemcitabine if condition worsens → FOLFIRINOX only if good patient condition status → Jan 2023: 1st line NALIRIFOX → New products
Slide 14: Positive Nadunolimab Efficacy Signals in 1st Line PDAC
Positive Nadunolimab Efficacy Signals in 1st Line PDAC OS for mITT patients Best responses according to iRECIST Nadunolimab combination with gemcitabine/nab-paclitaxel (GN) in 1st line metastatic PDAC (n=73): → 32% response rate → Additional 5 (7%) patients had on-treatment benefit beyond progressio
Slide 15: IL1RAP Expression in Tumor Biopsies from PDAC Patients
IL1RAP Expression in Tumor Biopsies from PDAC Patients IL1RAP expression in patient biopsies 300 200 H-score 100 0 n= igh n= ow H L 29 20 P P RA RA IL1 IL1 Differential expression of IL1RAP on tumor cells at baseline in PDAC patients: → IL1RAP expression on tumor cells analyzed by IHC on baseline pr
Slide 16: Stronger OS Benefits in High IL1RAP-Expressing Patients
Stronger OS Benefits in High IL1RAP-Expressing Patients (14.2 vs. 10.6 Months) IL1RAP High IL1RAP Low Efficacy analysis for IL1RAP High (n=29, 60%) vs. IL1RAP Low (n=20, 40%) in PDAC patients → High IL1RAP expression is a marker for poor prognosis after treatment with gem/nab-paclitaxel → Significan
Slide 17: Safety Profile CANFOUR PDAC
Safety Profile CANFOUR PDAC % of patients left in study with neutropenia Nadunolimab Gem/nab- Gem/nab- +Gem/nab- paclitaxel Grade 3 or higher paclitaxel paclitaxel NAPOLI 3, AEs MPACT, 2013 CANFOUR 2023 (n=421) (n=76) (n=379) Neutropenia 66% 38% 24% weeks Leukopenia 24% 31% 5% Thrombocytopenia 13% 1
Slide 18: IL1RAP and Alleviation of Neuropathy
IL1RAP and Alleviation of Neuropathy → Chemotherapy and ADCs induce neuropathy by several pathways including IL-1 (neuroinflammation) → High levels of inflammatory cytokines such as IL1β have been shown to correlate with higher risk of chemotherapy induced neuropathy1 → Preclinically, anti-IL1RAP mA
Slide 19: Neuropathy Clinical Data with nadunolimab
Neuropathy Clinical Data with nadunolimab Gemcitabine/nab-paclitaxel → Ph2 study data from CANFOUR in 1L PDAC patients Any grade neuropathy 1 mg/kg 2.5 mg/kg and above treated with nadunolimab and gemcitabine/nab- 80% 1 mg/kg Grade 1 Percent of patients 2.5 to 7.5 mg/kg Grade 1 paclitaxel 60% 15% 30
Slide 20: Future of PDAC Management – Two Targetable Pathways
Future of PDAC Management – Two Targetable Pathways with Strong Combination Potential → KRAS fuels IL-1 dependent tumor inflammation → Autocrine IL-1 activates IL1RAP and triggers tumor cell intrinsic IRAK-dependent signaling → IL-1 signaling shapes the TME by activating IL1RAP on myeloid cells and
Slide 21: Ph1b/2a in Combination with Nadunolimab + RASi
Preparation for Multiple Treatment Options: Ph1b/2a in Combination with Nadunolimab + RASi An open-label Phase 1b trial designed to assess safety and tolerability of nadunolimab combined with daraxonrasib in PDAC patients who had previously progressed on 1L SoC Survival Follow Up Study population: N
Slide 22: Myeloid Malignancies – MDS and AML
MYELOID MALIGNANCIES – MDS AND AML
Slide 23: MDS and AML – IL1RAP at the Center of Disease
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) – IL1RAP at the Center of Disease MDS: • Originates from IL1RAP+ leukemia stem cells (LSC) in the bone marrow (BM) • LSC produces immature, non-functional, blast cells, in MDS <20% of BM • Divided into low, intermediate and high risk •
Slide 24: Encouraging Leukemia Data Reinforce IL1RAP as a High-Risk Target
Encouraging Leukemia Data Reinforce IL1RAP as a High-Risk Target → IL1RAP is overexpressed in leukemic disease and linked to adverse inflammatory and signaling profiles → In AML, higher IL1RAP expression has been p=2.2 x 10-7 associated with poorer outcomes in independent clinical studies → Supports
Slide 25: IL1RAP Expression increases with Disease Aggressiveness
IL1RAP Expression increases with Disease Aggressiveness Relative IL1RAP expression across myeloid disease states Conceptual scale based on published flow-cytometry observations Key message Healthy hematopoietic stem cells (HSCs) Relative expression show very low or undetectable IL1RAP IL1RAP-high ex
Slide 26: High-risk MDS comprises ~35% of all new MDS cases
High-risk (HR) Myelodysplastic Syndrome (MDS) comprises ~35% of all new MDS cases Global Prevalence – Treatment (HMA) Unmet need Value MDS* • ~400.000 MDS patients Backbone (HMA) treatment: Stem Cell transplantation Delay leukemic (AML) • HR patients: ~ 35% – Vidaza (5-azacitidine) • (HSCT) - the on
Slide 27: Nadunolimab in MDS and AML – Targeting the Root Cause
Nadunolimab in MDS and AML – Targeting the Root Cause of the Disease → LSCs escape current chemotherapeutic treatment strategies, thereby providing a reservoir for disease relapse → Strong medical need for targeting LSCs with specificity → IL1RAP is expressed in AML and high-risk MDS → IL1RAP is exp
Slide 28: IIT at MD Anderson: Ph1b/2a Study in MDS/AML
IIT at MD Anderson: Ph1b/2a Study in MDS/AML Principal Investigator: Gautam Borthakur, MD, MD Anderson Cancer Center Grant support: U.S. Department of Defense (DOD) Study start 2025 Arm 1 HR-MDS (n=20): Cycle 1 Cycle 2-24 • Intermediate/high/very high risk MDS* • Untreated or up to 2 Treatment prior
Slide 29: Nadunolimab Studies
NADUNOLIMAB STUDIES
Slide 30: Ongoing Investigator-Initiated Trials with nadunolimab
Ongoing Investigator- Initiated Trials with nadunolimab Study Disease Combination therapy Number of Status NCT-number patients Leukemia* MDS/AML Azacitidine and/or 40 Recruiting NCT06548230 venetoclax Colorectal** MSS CRC Toripalimab (anti-PD-1) 24 Recruiting NCT07281716 Lung Cancer High-risk - Up t
Slide 31: Combining Nadunolimab with Immunotherapy in Metastatic MSS CRC
Combining Nadunolimab with Immunotherapy in Patients with Metastatic MSS CRC → The clinical study at Mount Sinai aims to investigate the combination of nadunolimab and immune checkpoint inhibitor (ICI) therapy in patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal
Slide 32: Treatment of High-Risk Lung Cancer Patients with nadunolimab
Treatment of High-Risk Lung Cancer Patients with nadunolimab → The investigator initiated clinical trial at Mount Sinai aims to determine if nadunolimab can induce regression of lung nodules in patients with risk of developing lung cancer. → There is evidence that IL-1 is involved in tumor initiatio
Slide 33: Nadunolimab – Properties and Clinical Studies
NADUNOLIMAB – PROPERTIES AND CLINICAL STUDIES
Slide 34: Nadunolimab mAb Properties
Nadunolimab mAb Properties • Nadunolimab is a humanized anti-IL1RAP monoclonal immunoglobulin G1 (IgG1) antibody with a molecular weight of 144 kDa (non-glycosylated) • It has 2 glycan moieties deficient of fucose in the Fc- region for enhanced antibody-dependent cellular Fields et al Front. Immunol
Slide 35: Overview of Clinical Studies with nadunolimab
Overview of Clinical Studies with nadunolimab Study (mITT) NCT Design Status number CANFOUR NCT03267316 Nadunolimab in combination with Completed (n=113 in gemcitabine/nab-paclitaxel in 1L PDAC and PDAC manuscript published combination) gemcitabine/cisplatin or carboplatin/pemetrexed CCR in NSCLC NS
Slide 36: CAN14 and CANXX
CAN14 and CANXX Next generation IL1RAP therapeutics CANXX is a program for new therapeutics and reagents comprising unique antibodies, reagents and knowledge around IL1RAP as a drug target. CAN10 was the first program originating from the CANXX platform, CAN14 is the second project, adding new featu
Slide 37: CANxx – a Generator for New Drugs and Reagents
CANxx – a Generator for New Drugs and Reagents • Knowledge of IL1RAP and its role in disease • A library of ~500 anti-IL1RAP clones within the CANxx platform • CANxx antibodies bind to different domains of IL1RAP and have different functional properties CANXX – A COMPREHENSIVE SOURCE FOR NEW DRUG P
Slide 38: Next Generation IL1RAP Therapeutics
Next Generation IL1RAP Therapeutics IL1RAP blockade is a potent way to block inflammation in preclinical and translational ex vivo models Bispecific mAbs Add new functionalities to IL1RAP blockade for stronger efficacy – tailor for specific diseases IL1RAP is expressed in a large number of solid and
Slide 39: CAN14 and IL1RAP-based Bispecific Antibodies
CAN14 and IL1RAP-based Bispecific Antibodies Anti-IL1RAP as a framework for efficacious treatments tailored for specific diseases Joints • Osteoarthritis • Rheumatoid arthritis • Gout Skin Intestine • Hidradenitis • Crohn's disease Suppurativa (HS) • Ulcerative colitis • Atopic dermatitis IL-1 CAN14
Slide 40: CAN10
CAN10 Opportunities in autoimmune/inflammatory diseases CAN10 is an Anti-IL1RAP antibody for treatment of autoimmune and inflammatory disease. By its binding to IL1RAP, CAN10 can block IL-1, IL-33 and IL-36 signaling pathways simultaneously. This unique function provides CAN10 with great potential f
Slide 41: Transformational CAN10 Deal with Otsuka
Transformational CAN10 Deal with Otsuka • Marks a transformative milestone for Cantargia – providing external validation of its antibody platform and CAN10 target mechanism • Demonstrates the scientific and commercial value of Cantargia’s technology in autoimmune and inflammatory diseases • Enables
Slide 42: CAN10 Provides a Unique Opportunity to Block IL-1 Super-family Signaling
CAN10 Provides a Unique Opportunity to Block IL-1 Super- family Signaling Joints • Osteoarthritis • Rheumatoid arthritis • Gout • The IL-1superfamily of ligands and receptors is primarily associated with acute and chronic inflammation¹ Skin Intestine • Hidradenitis • Crohn's disease • Strong evidenc
Slide 43: CAN10 is Developed to Block IL-1 Family with Precision
CAN10 is Developed to Block IL-1 Family with Precision • CAN10 blocks multiple IL-1 family signaling by targeting a single receptor – Binds crucial epitope on common accessory protein (IL1RAP) – Prevents signaling from IL-1α/β, IL-33 and IL- 36α/β/γ IL-1/33/36 cytokine mix • CAN10 has shown robust e
Slide 44: CAN10 FIH – Full blockade of both IL-36 and IL-1β Signaling
CAN10 FIH – Full blockade of both IL-36 and IL-1β Signaling • Inhibition of IL-36 and IL-1β signaling documented at Cmax (SAD and MAD) and day 8 (SAD) or 14 days after 3rd dose (MAD) long lasting effect IL-36 inhibition IL-1β inhibition IL-36 induced IL-6 release IL-36 induced IL-6 release Cmax (S
Slide 45: Intellectual Property & Regulatory
INTELLECTUAL PROPERTY & REGULATORY
Slide 46: Cantargia IP
Cantargia IP Proprietary Pipeline • Lead candidate anti-IL1RAP antibody CAN04 Expiry year 2035 Granted patents (e.g. Europe, USA, China, Japan) • Anti-IL1RAP for treatment of solid tumors Expiry year 2032 Granted patents (e.g. Europe, USA, China, Japan) • Anti-IL1RAP for treatment of hematological d
Slide 47: US Designation & Protections in Addition to Patents
US Designation & Protections in Addition to Patents • Fast Track Designation Benefits – Granted in 2025 for nadunolimab in high-level IL1RAP PDAC • Provides sponsors with frequent communication and meetings with the FDA, which can help clarify requirements and resolve issues quickly during drug deve
Slide 48: EU Designations & Protections in Addition to Patents
EU Designations & Protections in Addition to Patents • Orphan Drug designation in EU – Granted in 2021 for nadunolimab in pancreatic cancer • Grants market exclusivity period of 10 years from the date of marketing authorization during which no similar medicinal product can be placed on the market fo
Slide 49: Key Financials & Investment Highlights
KEY FINANCIALS & INVESTMENT HIGHLIGHTS
Slide 50: Key Financial and Share Information
Key Financial and Share Information Cantargia’s Cap Table, June 30, 2026 Financials Number of Capital/Votes → Cash position: SEK 210m (June 30, 2026)* Owner shares (%) Fourth Swedish National Pension Fund 23,551,565 9.47% → Runway: Mid-2028 (with current commitments) Avanza Pension 13,649,243 5.49%
Slide 51: A Global Leader in IL1RAP Antibody Development
A Global Leader in IL1RAP Antibody Development IL1RAP is a unique target with dual mechanism addressing inflammation and cancer biology High IL1RAP expression marks poor prognosis in multiple malignancies Nadunolimab is a versatile combination agent for chemotherapy, immunotherapy, and emerging trea
Slide 52: Thank you
Thank you Contact details: info@cantargia.com